Income Taxes - Narrative (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Oct. 31, 2024	Dec. 31, 2023
Income Tax Examination [Line Items]
Capitalized research and development	$ 59,709,000	$ 82,389,000
Gross deferred tax assets	434,178,000	366,357,000
Deferred tax assets, valuation allowance	428,947,000	359,440,000		$ 248,420,000
Uncertain tax positions	3,457,000	3,659,000		$ 400,000
Penalties or interest accrued on income taxes	0	0
ImmPACT Bio USA Inc.
Income Tax Examination [Line Items]
Gross deferred tax assets			$ 39,600,000
Deferred tax assets, valuation allowance			$ 39,600,000
Deferred tax assets, foreign tax attribute carryforwards	1,800,000	1,400,000
Tax Year 2028 | Capital Loss Carryforward
Income Tax Examination [Line Items]
Tax credit carryforwards	52,500,000
Federal and State
Income Tax Examination [Line Items]
Tax credit carryforwards	48,600,000	43,600,000
Federal
Income Tax Examination [Line Items]
Operating loss carryforwards not subject to expiration	868,600,000	$ 599,200,000
State
Income Tax Examination [Line Items]
Operating loss carryforwards subject to expiration	876,500,000
Foreign Tax Jurisdiction
Income Tax Examination [Line Items]
Operating loss carryforwards not subject to expiration	$ 7,500,000